International Psoriasis Council

International Psoriasis Council
subscribe
5   What's New
Search
subscribe
Search

Advancing Knowledge. Improving Care.

Meet Our Newest IPC Councilors: Experts in Psoriasis Care and Research

Join us in welcoming Irène Gallais Sérézal, Hazel Oon, Dharshini Sathishkumar, and Yu Sawada as IPC’s newest Councilors for 2023. Their appointment by the IPC Board of Directors in September reflects their dedication to advancing psoriasis research and enhancing patient care globally.

As IPC Councilors, they will provide valuable insights and guidance, leveraging their extensive expertise in psoriasis research, treatment, and education. Their involvement will further strengthen all IPC programs, events, and initiatives, ensuring that we continue to make significant advancements in the field. To learn more about their impressive backgrounds, we encourage you to explore their detailed biographies.

Let’s extend a warm welcome to Irène Gallais Sérézal, Hazel Oon, Dharshini Sathishkumar, and Yu Sawada to our community of IPC Councilors. Their addition reaffirms IPC’s commitment to driving positive change and progress in psoriasis care worldwide.

Irène Gallais Sérézal, PhD

Besancon University Hospital

Besançon, France

IPC Councilor

Bio

Hazel Oon, MD, MRCP, MMed Internal Medicine

National Skin Centre

Singapore, Singapore

IPC Councilor

Bio

Dharshini Sathishkumar, MBBS, MD, DDVL

Department of Dermatology, Christian Medical College

Vellore, India

IPC Councilor

Bio

Yu Sawada, MD

Department of Dermatology, University of Occupational and Environmental Health

Kitakyushu, Japan

IPC Councilor

Bio

Categories

Recent Posts

Next Generation of Leaders: 2025 IPC Fellows Transition to Jr. Councilors

VIEW

Highlights from the 2026 American Academy of Dermatology (AAD) Annual Meeting: Diagnostic Complexity, Therapeutic Advances, and Emerging Research

VIEW
A man in a suit smiles at the camera next to text that reads, World Psoriasis Experts Give Their Take on Current, Hot, or Controversial Topics like Biologics in Psoriasis Management. EXPERT COMMENTARY.

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

VIEW

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.
Subscribe

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »
Monday, April 27, 2026

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026